GlassScriptPhysician profile
Stephanie Price
NPI 1578097077
$1,990.31
in general payments reported to CMS, 2019-2025
20 companies · $93.46 in 2025
The $93.46 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $100 · 2021: $528 · 2022: $1,024 · 2023: $157 · 2024: $88.28 · 2025: $93.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.24 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $324.44 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $155.22 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.74 | 2021-2022 | |
| Lundbeck LLC | $121.58 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $119.01 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $105.67 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $94.11 | 2021-2023 | Spravato |
| Acadia Pharmaceuticals INC | $83.68 | 2022-2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $80.71 | 2022-2025 | |
| Allergan, INC. | $73.93 | 2020 | |
| Neurocrine Biosciences, INC. | $73.89 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $72.95 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $70.83 | 2022 | |
| Corium, LLC | $35.54 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $31.96 | 2020-2022 | |
| Almatica Pharma LLC | $28.97 | 2021-2022 | |
| Gilead Sciences, INC. | $14.05 | 2021 | |
| Neos Therapeutics, LP | $13.33 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.